RD Saúde Adjusted Profit Rises 23% as Digital Sales Surge
GLP-1 demand and market-share gains lift revenue 18%, while free cash flow turns positive and leverage…
RD Saúde (Raia Drogasil) is the largest drugstore chain in Brazil, with the Droga Raia and Drogasil banners.
RADL3 is the ticker of RD Saúde’s common shares (ON) on B3, listed in the Novo Mercado, the segment with B3’s strictest corporate-governance rules.
Company facts: CVM open data (Formulário Cadastral 2026), available under the ODbL. Descriptions by Brazil Stock Guide.
GLP-1 demand and market-share gains lift revenue 18%, while free cash flow turns positive and leverage…
A ruling against Drogasil questions whether retailers can make lower prices depend on customers handing over…
Retail pharmacy giant posts strong revenue growth and market-share gains as GLP-1 drugs and omnichannel sales…
Company opens 88 new stores, hits R$12.1 billion in sales and R$402 million in profit amid…
A Brazil Stock Guide investigation tracks campaign contributions from business figures linked to Grendene, Cosan, Amil…
GLP-1 drugs account for approximately 12% of sales, while operating margins narrow slightly.
CEO Carlos Marinelli says maturing hospital operations and oncology expansion should increase Atlântica Hospitais' contribution to…
Revenue climbs 9.2% to R$14.3 billion in the third quarter, but higher medical claims weigh on…
Backed by a planned $320 million loan from the BRICS development bank, the project aims to…
RADL3 is the ticker of RD Saúde’s common shares (ON) on B3, the São Paulo stock exchange, where the company is listed in the Novo Mercado, the segment with B3’s strictest corporate-governance rules.
Yes. Non-resident investors can buy shares listed on B3 through a Brazilian custodian after registering with the CVM, the Brazilian securities regulator.
The quote, chart, technical rating, company profile and financials on this page are TradingView widgets with B3 market data. The company facts come from the CVM public register, and the news from the Brazil Stock Guide newsroom.
Market data by TradingView. Informational only — not investment advice.